mProX™ Human NT5E Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;A549

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Cardiovascular Research

Related Diseases

Calcification Of Joints And Arteries; Periarthritis

Gene ID

Human:4907

UniProt ID

Human:P21589

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD73, encoded by the NT5E gene, is involved in various cellular processes and has been implicated in tumor development. In nasopharyngeal carcinoma (NPC), CD73 expression is higher in tumor tissues compared to normal tissues, and its expression is associated with clinical stages, lymph node metastasis, and prognosis of NPC patients. Knocking down CD73 in NPC cells inhibits their malignant phenotype. In a study on aortic inflammation, CD73 deficiency did not aggravate immune cell recruitment or affect morphological or functional characteristics. In pancreatic cancer, CD73 is part of an immunogenic cell death-related prognostic signature and is associated with poor overall survival. In HER2-positive breast cancer, CD73 is a marker of reversible senescence and can be targeted for ultrasound molecular imaging to evaluate lapatinib resistance. In non-small cell lung cancer (NSCLC), proteasome inhibitors reduce CD73 expression by decreasing p-ERK levels, a component of the MAPK pathway. CD73 overexpression in NSCLC cells reduces the anticancer activity of proteasome inhibitors in vivo. These findings suggest that CD73 plays important roles in tumor behavior and may serve as a diagnostic marker and therapeutic target in various cancers.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NT5E Stable Cell Line (S01YF-1023-PY282). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

What is the role of NT5E in cancer? Oct 23 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

NT5E (CD73) promotes the proliferation and metastasis of cancers like lung adenocarcinoma through pathways such as the EGFR/AKT/mTOR signaling pathway 1. It is also associated with an immunosuppressive tumor microenvironment, indicating its potential as a biomarker for cancer prognosis. Oct 23 2020

chat Taylor Brown (Verified Customer)

How does NT5E impact the immune system in diseases like systemic lupus erythematosus (SLE)? Sep 13 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

The AHR/TET2/NT5E axis downregulation is associated with the risk and progression of SLE, mediating Treg immunosuppressive activity and offering insights for therapeutic approaches. Sep 13 2021

Published Data

Fig.1 Increased CD73 expression suppresses LUAD cell apoptosis in vitro.

The decrease in apoptotic ratio was observed in A549 cells when CD73 expression was knocked down or when cells were subjected to APCP treatment, while an increase in apoptotic ratio was noted in A549 cell lines overexpressing CD73.

Ref: Zhang, Hong, et al. "CD73 (NT5E) promotes the proliferation and metastasis of lung adenocarcinoma through the EGFR/AKT/mTOR pathway." BioMed Research International 2022 (2022).

Pubmed: 35813221

DOI: 10.1155/2022/9944847

Research Highlights

Massold, Timo. et al. "CD73 deficiency does not aggravate angiotensin II-induced aortic inflammation in mice." Scientific reports, 2023.
The role of vascular inflammation in aortic diseases has been widely studied. CD73, an ecto-5'-nucleotidase that produces anti-inflammatory adenosine, has emerged as a potential target for treatment. This study aims to determine if the absence of CD73 leads to increased aortic inflammation. To investigate this, wildtype and CD73-deficient mice were infused with angiotensin II. Results suggest that CD73 may play a crucial role in mitigating aortic inflammation and could be a promising therapeutic target for aortic diseases.
Massold, Timo. et al. "CD73 deficiency does not aggravate angiotensin II-induced aortic inflammation in mice." Scientific reports, 2023.
Pubmed: 37816827 DOI: 10.1038/s41598-023-44361-7

Yu, Wenjing. et al. "Identification of immunogenic cell death,Äërelated prognostic signatures in pancreatic cancer." Oncology letters, 2023.
The present study aimed to clarify the role of immunogenic cell death (ICD)-related genes in pancreatic cancer and how targeting ICD may improve the response to immune checkpoint inhibitors (ICIs). Through the use of consensus clustering and k-means method, patients with pancreatic cancer were effectively grouped into two subtypes. A set of differentially expressed genes related to ICD were then identified, allowing for a comprehensive enrichment analysis. A prognostic signature (IRPS) was constructed using LASSO Cox regression to evaluate responses to both chemotherapy and immunotherapy. Experimental investigations further elucidated the biological functionality of 5'-nucleotidase ecto (NT5E). Patients belonging to the ICD high subtype had a significantly shorter overall survival and were notably correlated with HLA families and immune checkpoint molecules, highlighting their immunological significance. High IRPS risk scores were associated with resistance to immunotherapy interventions. Additionally, downregulation of NT5E in combination with Gemcitabine was found to induce tumor cell apoptosis, showcasing its potential therapeutic value. A novel classification system using ICD-related genes was developed to comprehensively assess clinical outcomes and therapeutic responses in patients with pancreatic cancer.
Yu, Wenjing. et al. "Identification of immunogenic cell death,Äërelated prognostic signatures in pancreatic cancer." Oncology letters, 2023.
Pubmed: 37809045 DOI: 10.3892/ol.2023.14061